IN8BIO, INC. Restricted Cash and Cash Equivalents
IN8BIO, INC. (INAB) had Restricted Cash and Cash Equivalents of $13.11 million as of 2023-09-30, per its 10-Q filed 2023-11-09.
Discontinued › Balance Sheet › Assets
us-gaap:RestrictedCashAndCashEquivalents · last filed 2023-11-09
- 2023-09-30: Restricted Cash and Cash Equivalents $13.11M.
- 2023-06-30: Restricted Cash and Cash Equivalents $17.25M.
- 2023-03-31: Restricted Cash and Cash Equivalents $11.11M.
- 2022-09-30: Restricted Cash and Cash Equivalents $27.90M.
| Period end | Restricted Cash and Cash Equivalents |
|---|---|
| 2023-09-30 | $13.11M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $17.25M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $11.11M 10-Q · filed 2023-05-12 |
| 2022-09-30 | $27.90M 10-Q · filed 2023-11-09 |
| 2022-06-30 | $25.99M 10-Q · filed 2023-08-10 |
| 2022-03-31 | $32.36M 10-Q · filed 2023-05-12 |
| 2021-09-30 | $40.67M 10-Q · filed 2022-11-10 |
| 2021-06-30 | $12.00M 10-Q · filed 2022-08-12 |
| 2021-03-31 | $15.05M 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| Pluri Inc. (PLUR) | $0.014B | ||
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B |